Topics

Lipella Pharmaceuticals, Inc. Company Profile

01:13 EST 26th February 2020 | BioPortfolio

Lipella Pharmaceuticals Inc., the developer of LP-09, is a specialty biopharmaceutical company focused on the development of topical liposomal formulations for multiple therapeutic applications, including Interstitial Cystitis, Hemorrhagic Cystitis, and Overactive Bladder. LP-09 is not currently approved for commercial use in any indication in the United States. Further company details are available at www.lipella.com.


News Articles [556 Associated News Articles listed on BioPortfolio]

FDA approves nine generic versions of Pfizer's Lyrica

The FDA has given its approval to the first generic versions of Pfizer’s Lyrica (pregabalin), it has emerged, giving the commercial green light to not one, but nine different analogue therapies. The...

Belgium’s UCB to buy Ra Pharmaceuticals for $2.1bn

Under the deal, Ra Pharmaceuticals shareholders will secure $48 in cash for each of its share at closing. Based in Cambridge of Massachusetts, Ra Pharma uses an advanced The post Belgium’s UCB to b...

Belgium’s UCB to buy Ra Pharmaceuticals for $ 2.1bn

Under the deal, Ra Pharmaceuticals shareholders will secure $48 in cash for each of its share at closing. Based in Cambridge of Massachusetts, Ra Pharma uses an advanced The post Belgium’s UCB to b...

BMS and BioMotiv launch Anteros Pharmaceuticals

Bristol-Myers Squibb (BMS) and drug development accelerator BioMotiv have launched biotechnology company Anteros Pharmaceuticals. Anteros Pharmaceuticals will work to develop...Read More... The post B...

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals Announces Leadership Update

BOSTON, MA / ACCESSWIRE / January 8, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® tec.....

GW Pharmaceuticals: Optimismus angebracht

Kulmbach (www.aktiencheck.de) - GW Pharmaceuticals-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die GW Pharmaceuticals-....

GW Pharmaceuticals: Überzeugende Quartalszahlen

Kulmbach (www.aktiencheck.de) - GW Pharmaceuticals-Aktienanalyse von "Der Aktionär": Marion Schlegel vom Anlegermagazin "Der Aktionär", nimmt in einer aktuellen Aktienanalyse die GW Pharmaceuticals....

Pieris Pharmaceuticals, Inc.: Pieris Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON, MA / ACCESSWIRE / August 29, 2019 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin tech...

Drugs and Medications [0 Results]

None

PubMed Articles [111 Associated PubMed Articles listed on BioPortfolio]

Mytilidae as model organisms in the marine ecotoxicology of pharmaceuticals - A review.

Growing production and consumption of pharmaceuticals is a global problem. Due to insufficient data on the concentration and distribution of pharmaceuticals in the marine environment, there are no app...

Occurrence and ranking of pharmaceuticals in the major rivers of China.

Residual pharmaceuticals have received widespread attention worldwide due to their continuous release and potential hazard to the environment. As a result of rapid development and a large population, ...

Analysis, occurrence and removal of pharmaceuticals in African water resources: A current status.

Pharmaceuticals are organic compounds used in medicines for alleviation of pain. Since 2017, there has been a steady increase on the availability of information on contamination of water resources cau...

Prioritization of pharmaceuticals in water environment in China based on environmental criteria and risk analysis of top-priority pharmaceuticals.

Numerous studies have shown that a wide range of pharmaceuticals are present in the environment and many of their adverse biological effects on the aquatic ecosystem and human health are unknown. Due ...

Biological-activity-based prioritization of pharmaceuticals in wastewater for environmental monitoring: G protein-coupled receptor inhibitors.

Pharmaceuticals raise concerns for aquatic species owing to their biological activities. It is estimated that nearly 40% of marketed pharmaceuticals target G protein-coupled receptors (GPCRs). Using a...

Clinical Trials [252 Associated Clinical Trials listed on BioPortfolio]

Bioequivalence Study of Torrent Pharmaceuticals's Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic 20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sepa...

Bioequivalence Study of Torrent Pharmaceuticals Ltd's Nebivolol 20 mg Tablet

Subjects to compare the single dose bioavailability of Torrent's Nebivolol Tablets 20 mg and Bystolic®20 mg Tablets of Forest Pharmaceuticals Inc., USA. Dosing periods of studies were sep...

Study Comparing Citalopram Hydrobromide Tablets 40 mg (Torrent Pharmaceuticals Ltd) and RLD Tablets 40 mg (Manufactured By Forest Pharmaceuticals Inc, Missouri) in 24+2 Normal Healthy Male Subjects in Fed Condition

- Objective: - The objective of this study is to compare the rate and extent of absorption of the Test Product, Citalopram Hydrobromide 40 mg (Torrent Pharmaceutical Li...

Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Rosuvastatin Calcium Tablets Under Fed Conditions

Subjects to compare the single dose bioavailability of Torrent's Rosuvastatin Calcium Tablets 40 mg and Crestor® 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA. Dosing periods of st...

Cilostazol 50 mg Tablets Under Fasting Conditions

This study will compare the relative bioavailability (rate and extent of absorption) of 50 mg Cilostazol Tablets manufactured by TEVA Pharmaceuticals Industries Ltd. and distributed by TEV...

Companies [1409 Associated Companies listed on BioPortfolio]

Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. is a privately held pharmaceutical company. For further company details, visit www.lipella.com

Lipella Pharmaceuticals, Inc.

Lipella Pharmaceuticals Inc., the developer of LP-09, is a specialty biopharmaceutical company focused on the development of topical liposomal formulations for multiple therapeuti...

Maelor Pharmaceuticals Ltd.

Maelor is a publicly listed (AIM:MLR) specialist critical care pharmaceuticals and devices company. The Company has developed an expertise in bringing both pharmaceuticals and devices to the market as...

Excaliard Pharmaceuticals, Inc.

Excaliard Pharmaceuticals, Inc., is a venture capital-funded biotechnology company founded in 2007 focused on the development and commercialization of novel and innovative drugs for the amelioration o...

Serenity Pharmaceuticals

Founded in 2007 and located in Milford, Pennsylvania, Serenity Pharmaceuticals is focused on developing products that address urinary conditions that impact the health and well-be...

More Information about "Lipella Pharmaceuticals, Inc." on BioPortfolio

We have published hundreds of Lipella Pharmaceuticals, Inc. news stories on BioPortfolio along with dozens of Lipella Pharmaceuticals, Inc. Clinical Trials and PubMed Articles about Lipella Pharmaceuticals, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Lipella Pharmaceuticals, Inc. Companies in our database. You can also find out about relevant Lipella Pharmaceuticals, Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks



Searches Linking to this Company Record